Results 131 to 140 of about 44,151 (306)

Pharmacodynamic Profile of Carvedilol

Cardiology, 1993
The combination of a beta blocker and a vasodilator is logical in the treatment of high blood pressure. Systemic arteriolar dilatation is beneficial to reduce the elevated peripheral resistance and hence to decrease cardiac afterload. beta-Adrenoceptor blockade exerts its own antihypertensive activity and also suppresses the reflex tachycardia induced ...
openaire   +3 more sources

Implementation of guideline‐directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa‐HF Registry)

ESC Heart Failure, Volume 12, Issue 3, Page 1786-1795, June 2025.
Abstract Aims The last released European guidelines on the management of heart failure (HF) recommend in patients with chronic HF with reduced ejection fraction (HFrEF) a pharmacological approach based on four fundamental drugs to be rapidly implemented and then uptitrated to modify disease progression.
Stefania Paolillo, Christian Basile, Federica Marzano, Dario Bruzzese, Piergiuseppe Agostoni, Irene Mattavelli, Angelo Aloisio, Pietro Ameri, Martina Solimano, Natale Daniele Brunetti, Paolo Calabrò, Arturo Cesaro, Matteo Cameli, Giulia Elena Mandoli, Erberto Carluccio, Chiara Belardinelli, Stefano Carugo, Laura Casalino, Emilia Chiuini, Deborah Cosmi, Frank Lloyd Dini, Mariafrancesca Di Santo, Gennaro Esposito, Ferdinando Ferrara, Maria Francesca Fierro, Gennaro Galasso, Luca Gallo, Antonella Rispoli, Paola Gargiulo, Francesco Grigioni, Andrea Segreti, Franco Guarnaccia, Natale Guarnaccia, Federico Guerra, Emanuele Cicchirillo, Ciro Indolfi, Mauro Larcher, Adele Lillo, Marco Metra, Roberta Montisci, Maria Francesca Marchetti, Savina Nodari, Francesco Fioretti, Ermanno Nardi, Ugo Oliviero, Alberto Palazzuoli, Giuseppe Patti, Marco Pepe, Filomena Pacelli, Fabrizio Perrone Filardi, Giuseppe Putortì, Giosuè Santoro, Michele Senni, Emilia D'Elia, Paolo Severino, Andrea D'Amato, Simona Soriano, Gianfranco Sinagra, Maddalena Rossi, Monica Franzese, Giovanni Smaldone, Giovanni Battista Zito, Pasquale Perrone Filardi   +62 more
wiley   +1 more source

Short‐Term Cardiovascular Sequelae Following In‐Office Posterior Nasal Nerve Cryoablation

Laryngoscope Investigative Otolaryngology, Volume 10, Issue 3, June 2025.
ABSTRACT Objective Evaluate the post‐procedural cardiovascular effects of posterior nasal nerve (PNN) cryoablation in comparison to inferior turbinate reduction (ITR). Methods Patients over 18 years of age who underwent in‐office PNN cryoablation or ITR via submucosal resection via radiofrequency ablation between 2019 and 2022 were enrolled ...
Jackson King, Lane D. Squires, Daniel Cates, Machelle Wilson, E. B. Strong, Toby Steele   +5 more
wiley   +1 more source

Is it time to replace propranolol with carvedilol for portal hypertension? [PDF]

, 2015
Beta-adrenergic receptor antagonists (beta-blockers) have been well established for use in portal hypertension for more than three decades. Different Non-selective beta-blockers like propranolol, nadolol, timolol, atenolol, metoprolol and carvedilol have
Abid, Shahab, Ali, Saadat, Baig, Muhammad Asif, Waheed, Anam Akbar   +3 more
core   +2 more sources

Monitoring Serum Bisoprolol Concentrations in Patients With Heart Failure With Reduced Ejection Fraction: Results of a Pilot Study From Routine Health Care

Pharmacology Research &Perspectives, Volume 13, Issue 3, June 2025.
ABSTRACT Bisoprolol is a second‐generation, highly selective beta‐1 adrenergic receptor antagonist with various beneficial effects in patients with heart failure. Interindividual variability in response to bisoprolol is known, and finding the optimal dose for individual patients with heart failure is still challenging.
Ivana Kacirova, Marie Lazarova, Romana Urinovska, Jozef Dodulik, Diana Drienikova, Jan Vaclavik   +5 more
wiley   +1 more source

Chronic treatment with Carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure [PDF]

, 2003
BACKGROUND: β-blocker treatment has emerged as an effective treatment modality for heart failure. Interestingly, β-blockers can activate both pro-apoptotic and anti-apoptotic pathways. Nevertheless, the mechanism for improved cardiac function seen with β-
Doye, Angelia A, Gwathmey, Judith K, Hajjar, Roger J, Jabbour, George, Laste, Nancy, Lebeche, Djamel, Lee, Michael X, Okafor, Chukwuka C, Perreault-Micale, Cynthia, Skiroman, Klara   +9 more
core   +2 more sources

Carvedilol in Heart Failure

Cardiology, 1993
Sustained oral treatment with beta blockers has been shown to improve symptoms in patients with chronic heart failure. In non-placebo-controlled trials, the administration initially of a low dose, gradually increased over a period of weeks has been demonstrated to improve both symptoms, exercise capacity and left-ventricular ejection fraction.
openaire   +3 more sources

Lactate orchestrates metabolic hemodynamic adaptations through a unique combination of venocontraction, artery relaxation, and positive inotropy

Acta Physiologica, Volume 241, Issue 5, May 2025.
Abstract Aim H+ facilitates metabolic blood flow regulation while negatively impacting cardiac contractility. Cardiovascular consequences of conjugate bases accumulating alongside H+ remain unclear. Here, we evaluate the cardiovascular effects of nine prominent carboxylates—particularly lactate, 3‐hydroxybutyrate, and butyrate—linked to metabolic and ...
Casper Homilius, Jacob M. Seefeldt, Jakob Hansen, Roni Nielsen, Frank V. de Paoli, Ebbe Boedtkjer   +5 more
wiley   +1 more source

A Prospective, Randomized, Double-Blind Comparison of the Long-Term Effects of Metoprolol Versus Carvedilol [PDF]

, 2000
Background—Both metoprolol and carvedilol produce hemodynamic and clinical benefits in patients with chronic heart failure; carvedilol exerts greater antiadrenergic effects than metoprolol, but it is unknown whether this pharmacological difference ...
Boldi, Emiliano, Cas, Livio Dei, Giubbini, Raffaele, Metra, Marco, Modena, Maria Grazia, Nodari, Savina   +5 more
core   +1 more source

Chemoprevention of Gastrointestinal Cancers: An Umbrella Review of Meta‐Analyses of Randomized Controlled Trials and Cohort Studies

Clinical and Translational Science, Volume 18, Issue 5, May 2025.
ABSTRACT Several meta‐analyses have investigated the association between chemopreventive agents (CPAs) and the risk of gastrointestinal cancers, but syntheses of the quality of evidence in aggregate are lacking. This umbrella review aimed to assess the quality of evidence from meta‐analyses of randomized controlled trials (RCTs) and cohort studies that
Jia En Chan, Suresh Shanmugham, Suresh Kumar, Yeong Yeh Lee, Siew Mooi Ching, Nathorn Chaiyakunapruk, Sajesh K. Veettil   +6 more
wiley   +1 more source